Loading clinical trials...

TopQ Cut-off Score Validation Study for 3D OCT-1 Maestro | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT02447133

TopQ Cut-off Score Validation Study for 3D OCT-1 Maestro

The objective of this study is to validate the TopQ cutoff scores, which have been previously determined.

Lead sponsor: Topcon Medical Systems, Inc.•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment12

Start dateMay 2015

Last updatedJun 29, 2022

Condition

Subjects Presenting With Normal Eyes

Locations shown

Topcon Medical Systems, Inc.

Oakland, New Jersey

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 29, 2022Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions